Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Travere Therapeutics, Inc. (TVTX)
A forensic read on Travere Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
6.8
Distress distance
Watch
Earnings quality
6
Forensic signals
-135.4
P / E (ttm)
-22.2%
ROE
$5.8B
Market cap
0.00%
Dividend yield
110.5%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Travere Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 6.8, placing it in the Safe zone. 6 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+190.3%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +190.3% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The build is led by receivables up +196% against revenue +110%. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 567% of net operating assets, diverging from the balance-sheet accrual read.
-14.1%
FY2025
Return on invested capital.Return on invested capital is -14.1% in the latest fiscal year and rising from -54% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+11.8%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +40% over the last 3 years to FY2025 (+11.8%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~11.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~29%.
9% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 9% of revenue in FY2025 — about $0.50 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 11.9% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.
Key fundamentals
Latest Revenue$490.7M
Revenue Growth YoY+110.5%
Revenue CAGR (3yr)+64.9%
Net Margin-5.2%
Return on Equity-22.2%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Travere Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.
Travere Therapeutics, Inc. (TVTX) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
stopped
FY2013→FY2016
Shareholder returns — halted.Capital returns have STOPPED — $958,000 of buybacks + dividends in FY2013, but ~$0 in FY2016. A halt usually means the company is conserving cash.
-$479.7M
FY2023–FY2025
Cash burn vs. reported loss.Over FY2023–FY2025, the company reported a cumulative net loss of $458.5M against operating cash flow of -$479.7M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.